Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osteostatin
- Development stage
- Preclinical
- Lead developer
- Complutense University of Madrid
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Osteostatin is a pentapeptide fragment corresponding to amino acids 107-111 (Thr-Arg-Ser-Ala-Trp or TRSAW) of the C-terminus of parathyroid hormone-related protein (PTHrP). It is widely studied in preclinical models for its osteogenic, anti-resorptive, and anti-inflammatory properties. Osteostatin has been shown to stimulate osteoblast differentiation and bone formation while inhibiting osteoclastogenesis and bone resorption. It is being investigated for potential applications in bone regeneration, osteoporosis, fractures, and inflammatory joint conditions such as rheumatoid arthritis and gouty arthritis, as well as its role in breast cancer bone colonization.
- Other names
- parathyroid hormone-related protein (107-111)PTHrP (107-111)PTHrP 107-111PTHrP107-111PTHrP-107-111TRSAW
Beyond the preview
Go deeper on osteostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osteostatin.